Transparency data

Non-tech summaries 2016: projects on nervous/mental disorders

Projects granted during 2016 that have a primary purpose of translational applied research - human nervous and mental disorders.

From:
Home Office
Published
21 December 2017

Documents

Non-technical summaries: projects granted in 2016, volume 19

PDF, 624 KB, 84 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This document outlines the projects granted under the Animals (Scientific Procedures) Act 1986 during 2016 with a primary purpose of translational applied research - human nervous and mental disorders.

The following projects were granted:

  • developing therapies for perinatal diseases (lack of oxygen, brain haemorrhage)

  • neurovascular function in health and disease (brain, blood vessels, alzheimer’s disease, energy, pericyte)

  • assessment of blood brain barrier transporters (drug discovery; blood brain barrier)

  • modulating autophagy tct tackle huntington’s disease (autophagy, cell death, huntington’s disease)

  • translational pharmacology for drug discovery (pharmacology, drug, discovery)

  • electrophysiological studies of neurodegenerative disorders (neurodegeneration, drug discovery, electrophysiology, in vivo)

  • anaesthesia and the developing brain (anaesthesia, neurodegeneration, neuro-apoptosis, developing brain)

  • gene transcription events mediating brain and behaviour (epigenetics; post-transcriptional modification; imprinted genes; behaviour; brain)

  • examining the role of mitochondria in neurodegeneration and vascular disorders (alzheimers, blood vessels, mitochondria, neurodegeneration)

  • using zebrafish to understand disease and develop therapies (zebrafish, development, disability, therapy, mechanism)

  • pharmacodynamics and pharmacokinetics of novel compounds (drug discovery, receptor, pharmacokinetic, pharmacodynamic)

  • MK2 as a regulator of inflammation in alzheimer’s (alzheimer’s, inflammation, hippocampus, synaptic plasticity, behaviour.)

  • neural signalling and disease in rodents (motoneurone, mechanosensation, MND, hypertension)

  • repair in neurodegenerative disease and injury (central nervous system, nerve cells, neurodegenerative diseases, regeneration)

  • role of D1R-D3R heteromers in l-DOPA-induced dyskinesias (parkinson’s disease, dyskinesia, dopamine, heteromers, glutamate receptors)

  • maintenance and regeneration of the nervous system (avulsion, neurodegeneration)

  • determination of CNS efficacy and safety pharmacology (central nervous system, behaviour, safety)

  • zebrafish and medaka as models for the study of psychiatric disease and age-related cognitive decline (zebrafish, behaviour, addiction, genetic modification, ageing)

  • early life exposure to drugs and environmental complexity and neuropsychiatric disorder (genetics, nature/nurture, environmental complexity)

  • neurological disorders: mechanisms and therapies (behaviour, cognition, brain, neurological disorder)

  • analgesic potential of retargeted SNARE proteases (analgesia, pain, neuropathic, post-operative, inflammatory)

  • CNS neurotransmitter action in health and disease (brain, neurodevelopmental disorders, neurodegeneration, neuron, glia)

  • improving the treatment of parkinson’s disease and parkinson’s disease dementia (parkinson’s disease, dementia, better treatments, cell protection, cell repair)

  • neuropharmacology and therapeutics in addiction and other dopamine-associated disorders (addiction, parkinson’s disease, treatments, neurogenesis)

Published 21 December 2017

Related content